Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 10257-10267

  Zhijun, Huang ^a,b   Shusheng, Wang ^c   Han, Min ^d   Jianping, Li ^a,b   Li sen, Qin ^e   Dechun, Li ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Department of Endocrinology   (China)

^c Suzhou Medical College of Soochow University   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e Third Hospital of Yancheng   (China)

Author keywords

4SC 202; AKT; Chemo sensitization and pre clinical studies; Colorectal cancer (CRC); Histone deacetylase (HDAC)

Indexed keywords

4SC 202; CASPASE 3; CASPASE 9; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; OXALIPLATIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; 4SC-202; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84983672067     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4868-6     Document Type: Article

References (30)

1. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015;12:73–4.
2. Schmoll HJ, Stein A. Colorectal cancer in 2013: towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol. 2014;11:79–80.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29.
4. McCarthy N. Colorectal cancer: editing an invasion. Nat Rev Cancer. 2014;14:297.
5. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening—optimizing current strategies and new directions. Nat Rev Clin Oncol. 2013;10:130–42.
6. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673–91.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.
8. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12:917–30.
9. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L, et al. Distinct and redundant functions of histone deacetylases hdac1 and hdac2 in proliferation and tumorigenesis. Cell Cycle. 2011;10:406–12.
10. Witt O, Deubzer HE, Milde T, Oehme I. Hdac family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
11. Mariadason JM. Hdacs and hdac inhibitors in colon cancer. Epigenetics. 2008;3:28–37.
12. Maes T, Carceller E, Salas J, Ortega A, Buesa C. Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol. 2015;23:52–60.
13. Li C, Cui JF, Chen MB, Liu CY, Liu F, Zhang QD, et al. The preclinical evaluation of the dual mtorc1/2 inhibitor ink-128 as a potential anti-colorectal cancer agent. Cancer Biol Ther. 2015;16:34–42.
14. Qin LS, Jia PF, Zhang ZQ, Zhang SM. Ros-p53-cyclophilin-d signaling mediates salinomycin-induced glioma cell necrosis. J Exp Clin Cancer Res. 2015;34:57.
15. Qin LS, Yu ZQ, Zhang SM, Sun G, Zhu J, Xu J, et al. The short chain cell-permeable ceramide (c6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. Mol Biol Rep. 2013;40:5645–55.
16. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, et al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via akt dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011;2:e117.
17. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19.
18. Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF. Abrogation of mitogen-activated protein kinase and akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J Pharmacol Exp Ther. 2009;331:327–37.
19. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through akt and erk1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 2005;65:2422–32.
20. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase b activation. Mol Cancer Ther. 2003;2:1093–103.
21. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. Mk-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956–67.
22. Afifi MM, Austin LA, Mackey MA, El-Sayed MA. Xav939: from a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles. Bioconjug Chem. 2014;25:207–15.
23. Palta M, Czito BG, Willett CG. Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. Nat Rev Clin Oncol. 2014;11:182–4.
24. Weihong X, Bin X, Yiting Y, Xiaoling Y, Jie S. The novel hdac inhibitor ar-42-induced anti-colon cancer cell activity is associated with ceramide production. Biochem Biophys Res Commun. 2015.
25. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
26. Chen CS, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem. 2005;280:38879–87.
27. Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32:92.
28. Chung KY, Saltz LB. Adjuvant therapy of colon cancer: current status and future directions. Cancer J. 2007;13:192–7.
29. O’Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol. 2009;27:3082–4.
30. Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage iii colon cancer. Br J Cancer. 2006;95:1195–201.